摘要
新型冠状病毒(2019-nCoV)感染所致不明原因肺炎疫情于2019年12月在湖北省武汉市暴发,并迅速传播到中国多地及其他国家。目前无确认有效的抗病毒治疗方法。曾有报道,甘草酸具有抗炎、保肝、抗病毒、抗氧化、抗肺纤维化及调节免疫等多种药理作用。为探讨甘草酸二胺在普通型新型冠状病毒肺炎(Novel coronavirus pneumonia,NCP)患者治疗中的临床价值,本研究按照随机数字法将我院收治的104例普通型NCP患者分为观察组与对照组,每组52例。对照组患者按照《新型冠状病毒感染的肺炎诊疗方案(试行第五版)》进行治疗,观察组患者在此基础上加用甘草酸二胺肠溶胶囊(150mg/次,3次/d),均连续治疗2周。之后观察2组的临床疗效,比较2组的C反应蛋白(C-reactive protein,CRP)、白细胞介素-4(Interleukin-4,IL-4)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)三项炎性指标以及CD3^+、CD4^+、CD8^+、CD4^+/CD8^+四项免疫功能指标,并观察不良反应发生情况。结果显示,观察组的痊愈率、显效率、总有效率分别为19.23%、28.85%、61.54%,均明显高于对照组(7.69%、17.31%、40.38%)(P<0.05)。治疗后,观察组的血清CRP、IL-4、TNF-α水平均明显低于对照组(P<0.05);观察组的CD3^+、CD4^+、CD8^+、CD4^+/CD8^+均明显高于对照组(P<0.05)。观察组的不良反应发生率(15.38%)明显低于对照组(28.85%)(P<0.05)。本研究提示,甘草酸二胺治疗普通型NCP患者的临床疗效显著,安全性高,能够明显抑制机体的炎性反应、提高免疫功能。
To determine the clinical value of diammonium glycyrrhizinate(DG)in treatment of patients with novel coronavirus pneumonia(NCP). According to the random-number method,104 NCP patients were divided equally into control group and observation group in our hospital. In the control group,patients were treated according to the Pneumonia diagnosis and treatment scheme for new coronavirus infection(trial version5). In the observation group,patients were administered DG enteric capsules(150 mg,t. d. s.). All patients were treated continuously for 2 weeks. The clinical effects in both groups were observed. Levels of inflammation indicators[C-reactive protein(CRP),interleukin(IL)-4,tumor necrosis factor(TNF)-α] and immunefunction indicators[cluster of differentiation(CD)3^+,CD4^+,CD8^+,CD4^+/CD8^+]were compared between the two groups. Adverse reactions were documented. The prevalence of cure[19.23%(10/52)vs. 7.69%(4/52)],significant efficacy [28.85%(15/52) vs. 17.31%(9/52)] and total efficacy [61.54%(32/52) vs.40.38%(20/52)]of the observation group was significantly higher than that of the control group(P<0.05 for all). After treatment,the serum levels of CRP[(1.90±0.85)vs.(3.26±1.63)mg/L],IL-4[(21.35±8.90)vs.(26.24±9.16)pg/mL],and TNF-α[(4.85±2.15)vs.(7.97±3.36)pg/mL]of the observation group were significantly lower than those of the control group(P<0.05 for all). The levels of CD3^+[(66.30±8.83)% vs.(54.19±7.79)%],CD4^+[(39.42±4.72)% vs.(33.18±4.10)%],CD8^+[(28.14±4.22)% vs.(23.39±3.88)% ],and CD4^+/CD8^+[(1.62 ±043) vs.(1.21±0.29)] of the observation group were significantly higher than those of the control group(P<0.05 for all). The prevalence of adverse reactions[15.38%(8/52)vs. 28.85%(15/52)]of the observation group was significantly lower than that of the control group(P<0.05). DG has a significant clinical effect and a good safety profile for NCP treatment.
作者
周外民
赵富明
李榜龙
田中秋
ZHOU Waimin;ZHAO Fuming;LI Banglong;TIAN Zhongqiu(The First Hospital of Changsha City,Changsha 410000,China;Hunan Chest Hospital,Changsha 41000,China)
出处
《病毒学报》
CAS
CSCD
北大核心
2020年第2期160-164,共5页
Chinese Journal of Virology
关键词
新型冠状病毒肺炎(NCP)
普通型
甘草酸二胺
免疫功能
炎性反应
Novel coronavirus pneumonia(NCP)
Common type
Diammonium glycyrrhizinate
Immune function
Inflammatory response
